Skip to main content
Caplight Logo









Hangzhou Huasai Biomedicine Co., Ltd.

Hangzhou Huasai Biomedicine Co., Ltd.

Private
HangzhouHealthcare & Life Scienceshttps://www.huasaibiomed.com/

Last Round

Series A

Dec 28, 2023

Company Overview

Hangzhou Huasai Biomedicine Co., Ltd. is a biopharmaceutical company that develops innovative cell therapies, specifically focusing on tumor-infiltrating lymphocyte (TIL) therapies for the treatment of solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

tumor-infiltrating lymphocyteTIL therapycell therapysolid tumor treatmentbiopharmaceuticalclinical trialimmunotherapycancer researchdrug developmentprecision medicinebiotechoncology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Hangzhou Huasai Biomedicine Co., Ltd. Comparables

Compare Hangzhou Huasai Biomedicine Co., Ltd. with similar companies based on industry and business-model similarity.

Hangzhou Huasai Biomedicine Co., Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Suzhou Lanma Medical Technology Co., Ltd.
90%
Grit Biotherapeutics
89%
Shanghai Juncell Therapeutics Co., Ltd.
89%

Hangzhou Huasai Biomedicine Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ADec 28, 2023
Pre SeedDec 21, 2021

Hangzhou Huasai Biomedicine Co., Ltd. Investors

Notable investors and investment history

Hangzhou Huasai Biomedicine Co., Ltd. investors
InvestorRounds
Letong CapitalSeries A
澳银资本Pre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 28, 2023

    Raised Series A with Letong Capital and Qingdao Beian Holdings.

Hangzhou Huasai Biomedicine Co., Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Hangzhou Huasai Biomedicine Co., Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Hangzhou Huasai Biomedicine Co., Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersHangzhou
Year Founded2019
Last FundingDec 28, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?